Rigel Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 85   

Articles published

RIGL 2.88 -0.12 (-4.00%)
price chart
Company Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rally 1.7%
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rose by 1.7% in the past week and 0.34% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.78% and the outperformance increases to 6.14% for the last 4 weeks.
Rigel Pharmaceuticals, Inc. Analyst Rating Update
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has received a short term rating of buy from research analysts at Zacks with a rank of 2. The company has been rated an average of 2 by 2 Wall Street Analysts.
Why Shares of Rigel Pharmaceuticals Inc. Exploded Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Pharmalot, Pharmalittle: We're Reading About Merck, Valeant and Much More!!  Wall Street Journal (blog)
Five things for pharma marketers to know: Monday, February 23  Medical Marketing and Media
Rigel Pharmaceuticals, Inc. Short Interest Update
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has witnessed a rise of 2.6% or 60,625 shares in its short figure. The short interest augmentation took it from 2,370,409 on July 31,2015 to 2,431,034 on August 14,2015.
Rigel Pharmaceuticals, Inc. – Product Pipeline Market Review – 2014: Radiant ...
This report provides comprehensive information on the current therapeutic developmental pipeline of Rigel Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), ...
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Drops by -5.37%
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has lost 5.37% during the past week and dropped 9.32% in the last 4 weeks.
Analyst Rating Update on Rigel Pharmaceuticals, Inc.  American Trade Journal
Rigel Pharmaceuticals Upgraded by Zacks to "Buy" (RIGL)  Dakota Financial News
Here's Why Rigel Pharmaceuticals, Inc. (RIGL) Stock Is Trading Up By 37% Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) will collaborate for the finding, marketing, and development of cancer immunotherapies with Bristol-Myers Squibb Co (NYSE:BMY), according to a press release reported on Monday.
Is Rigel Getting Enough From Bristol-Meyers?  24/7 Wall St.
Rigel and Bristol-Myers Squibb Announce Research and Development ...  PR Newswire (press release)
Zacks Short Term Rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
Analysts at Zacks have given a short term rating of buy on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with a rank of 2. The shares have received an average rating of 2 from 2 brokerage firms.
Company Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Drops by -2.84%
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has lost 2.84% during the past week and dropped 13.29% in the last 4 weeks.
Company Shares of Rigel Pharmaceuticals, Inc. Rally 1.36%
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) appreciated by 1.36% during the past week but lost 2.3% on a 4-week basis.
Rigel Pharmaceuticals (RIGL) Scheduled to Post Earnings on Tuesday  WKRB News